Therefore, the amount of the mutant receptor on the endothelial cell surface would be considerably higher and may contribute to the development of lymphoedema by reducing the relative amount of ligand binding to the active wild-type FLT4/VEGFR3. The gene discussed is FLT4; the disease is lymphedema.